Fostamatinib
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
- Fostamatinib
- Fostamatinib: From Chronic Immune Thrombocytopenia (ITP) to Autosomal Thrombocytopenia with Normal Platelets
Fostamatinib: From Chronic Immune Thrombocytopenia (ITP) to Autosomal Thrombocytopenia with Normal Platelets
One-Sentence Summary
Fostamatinib is a Syk (spleen tyrosine kinase) inhibitor approved for chronic immune thrombocytopenia (ITP), where it blocks FcγR-mediated destruction of antibody-coated platelets. The TxGNN model predicts it may be effective for Autosomal Thrombocytopenia with Normal Platelets, a hereditary, non-immune platelet disorder, but this prediction is currently supported by no clinical trials and no published literature — the connection appears to be a knowledge-graph artifact based on shared “thrombocytopenia” terminology rather than a validated mechanistic link.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Chronic Immune Thrombocytopenia (ITP) |
| Predicted New Indication | Autosomal Thrombocytopenia with Normal Platelets |
| TxGNN Prediction Score | 99.45% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Fostamatinib is a Syk inhibitor. Its approved mechanism in chronic ITP is to block FcγR signaling in macrophages, preventing the phagocytic destruction of platelets that have been coated with autoantibodies — an immune-mediated mechanism.
Autosomal thrombocytopenia with normal platelets is a hereditary condition typically caused by genetic mutations affecting platelet production or function, not by antibody-mediated platelet clearance. There is no established biological pathway linking Syk inhibition to correction of an inherited platelet-production defect.
Given this mismatch, the high TxGNN score most likely reflects a surface-level semantic association (both conditions contain “thrombocytopenia”) rather than a genuine shared mechanism. This prediction should be treated as a hypothesis-generation signal only, not as mechanistically validated.
Note: A second, lower-ranked prediction (non-syndromic esophageal malformation, score 99.05%) was also generated but shows no plausible biological link to Syk inhibition — Syk is expressed almost exclusively in hematopoietic/immune cells and has no known role in esophageal embryogenesis. This candidate is not pursued further.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no clinical trial or literature support (L5, evidence-only from the model), and the proposed mechanistic link is biologically implausible — ITP’s immune-mediated pathway does not map onto a hereditary, non-immune platelet disorder. In addition, a Blocking data gap (missing TFDA label/warnings) prevents even an initial safety assessment.
To proceed, the following is needed:
- TFDA/FDA label data — key warnings and contraindications (currently unavailable, Blocking gap)
- Confirmed detailed mechanism of action data beyond the general Syk-inhibitor class description
- Preclinical or mechanistic studies specifically testing Syk inhibition in hereditary thrombocytopenia models
- Drug interaction (DDI) data (current query returned no results)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.